|
|
Vaccine Detail
|
Melan-A VLP Vaccine |
| Vaccine Information |
- Vaccine Name: Melan-A VLP Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007508
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- MLANA
gene engineering:
- Type: Recombinant protein preparation
- Description: (Braun et al., 2012)
- Detailed Gene Information: Click Here.
- Description: A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response. (NCIT_C61495).
|
| Host Response |
|
|
| References |
Braun et al., 2012: Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P. Virus-like particles induce robust human T-helper cell responses. European journal of immunology. 2012; 42(2); 330-340. [PubMed: 22057679].
NCIT_C61495: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C61495]
|
|
